Is there added value of the hepatobiliary phase of MRI with hepatobiliary contrast agents for hepatocellular carcinoma diagnosis? : a meta-analysis

2024
journal article
article
dc.abstract.enPurpose: So far, there have been published several meta-analyses which focused on hepatocellular carcinoma (HCC) detection with hepatobiliary phase (HBP) contrast agents. However, only a few of them aimed at establishing whether there is any added value of the HBP itself for HCC diagnosis. To answer the question, we performed a systematic literature search with the time limit going back to 2010. Material and methods: True positive, false positive, false negative, and true negative values with and without the HBP were extracted from the included studies. Pooled sensitivities and specificities with and without the HBP were calculated and summary receiver operating characteristics curves were drawn to assess the diagnostic performance of the studies with and without the HBP. Results: A total of 13 studies were included involving 1184 HCC lesions. In 13 studies without the HBP, the pooled sensitivity, specificity, and area under the curve (AUC) were 0.83, 0.89 and 0.94 respectively. In 13 studies with the HBP, the pooled sensitivity, specificity and AUC were 0.91, 0.85 and 0.98 respectively. Conclusions: We found no statistically significant differences in sensitivities between studies with and without the HBP (p = 0.1651).
dc.contributor.authorRybczynska, Dorota
dc.contributor.authorMarkiet, Karolina
dc.contributor.authorPienkowska, Joanna
dc.contributor.authorFrydrychowski, Andrzej
dc.date.accessioned2025-08-18T07:29:35Z
dc.date.available2025-08-18T07:29:35Z
dc.date.createdat2025-08-18T07:29:35Zen
dc.date.issued2024
dc.date.openaccess0
dc.description.accesstimew momencie opublikowania
dc.description.additionalBibliogr. s. e412-e413
dc.description.physicale402-e413
dc.description.versionostateczna wersja wydawcy
dc.description.volume89
dc.identifier.doi10.5114/pjr/189614
dc.identifier.issn1733-134X
dc.identifier.projectDRC AI
dc.identifier.urihttps://ruj.uj.edu.pl/handle/item/559011
dc.languageeng
dc.language.containereng
dc.rightsUdzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Bez utworów zależnych 4.0 Międzynarodowa
dc.rights.licenceCC-BY-NC-ND
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/legalcode.pl
dc.share.typeotwarte czasopismo
dc.source.integratorfalse
dc.subject.encontrast agents
dc.subject.enhepatocellular carcinoma
dc.subject.enmeta-analysis
dc.subtypeArticle
dc.titleIs there added value of the hepatobiliary phase of MRI with hepatobiliary contrast agents for hepatocellular carcinoma diagnosis? : a meta-analysis
dc.title.journalPolish Journal of Radiology
dc.typeJournalArticle
dspace.entity.typePublicationen
dc.abstract.en
Purpose: So far, there have been published several meta-analyses which focused on hepatocellular carcinoma (HCC) detection with hepatobiliary phase (HBP) contrast agents. However, only a few of them aimed at establishing whether there is any added value of the HBP itself for HCC diagnosis. To answer the question, we performed a systematic literature search with the time limit going back to 2010. Material and methods: True positive, false positive, false negative, and true negative values with and without the HBP were extracted from the included studies. Pooled sensitivities and specificities with and without the HBP were calculated and summary receiver operating characteristics curves were drawn to assess the diagnostic performance of the studies with and without the HBP. Results: A total of 13 studies were included involving 1184 HCC lesions. In 13 studies without the HBP, the pooled sensitivity, specificity, and area under the curve (AUC) were 0.83, 0.89 and 0.94 respectively. In 13 studies with the HBP, the pooled sensitivity, specificity and AUC were 0.91, 0.85 and 0.98 respectively. Conclusions: We found no statistically significant differences in sensitivities between studies with and without the HBP (p = 0.1651).
dc.contributor.author
Rybczynska, Dorota
dc.contributor.author
Markiet, Karolina
dc.contributor.author
Pienkowska, Joanna
dc.contributor.author
Frydrychowski, Andrzej
dc.date.accessioned
2025-08-18T07:29:35Z
dc.date.available
2025-08-18T07:29:35Z
dc.date.createdaten
2025-08-18T07:29:35Z
dc.date.issued
2024
dc.date.openaccess
0
dc.description.accesstime
w momencie opublikowania
dc.description.additional
Bibliogr. s. e412-e413
dc.description.physical
e402-e413
dc.description.version
ostateczna wersja wydawcy
dc.description.volume
89
dc.identifier.doi
10.5114/pjr/189614
dc.identifier.issn
1733-134X
dc.identifier.project
DRC AI
dc.identifier.uri
https://ruj.uj.edu.pl/handle/item/559011
dc.language
eng
dc.language.container
eng
dc.rights
Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Bez utworów zależnych 4.0 Międzynarodowa
dc.rights.licence
CC-BY-NC-ND
dc.rights.uri
http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode.pl
dc.share.type
otwarte czasopismo
dc.source.integrator
false
dc.subject.en
contrast agents
dc.subject.en
hepatocellular carcinoma
dc.subject.en
meta-analysis
dc.subtype
Article
dc.title
Is there added value of the hepatobiliary phase of MRI with hepatobiliary contrast agents for hepatocellular carcinoma diagnosis? : a meta-analysis
dc.title.journal
Polish Journal of Radiology
dc.type
JournalArticle
dspace.entity.typeen
Publication
Affiliations

* The migration of download and view statistics prior to the date of April 8, 2024 is in progress.

Views
18
Views per month
Views per city
Krakow
11
Wroclaw
2
Puchong
1
Warsaw
1
Downloads
rybczynska_et-al_markiet_pienkowska_frydrychowski_is_there_added_value_of_the_hepatobiliary_phase_2024.pdf
28